Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEHDI MIRSAEIDI

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1285961680
CMS profile
1363365
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,554.98

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEHDI MIRSAEIDI

NPI 1285961680 · CMS profile ID 1363365

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285961680?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEHDI MIRSAEIDI, NPI 1285961680, CMS profile ID 1363365. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285961680?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MEHDI MIRSAEIDI, NPI 1285961680, CMS profile ID 1363365. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285961680?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MEHDI MIRSAEIDI, NPI 1285961680, CMS profile ID 1363365, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1285961680?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $6,554.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $123.2212/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222846143 CMS
Mallinckrodt Hospital Products Inc. $4.7510/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983867 CMS
Mallinckrodt Hospital Products Inc. $244.1810/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211983853 CMS
Mallinckrodt Hospital Products Inc. $64.2410/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211983855 CMS
Mallinckrodt Hospital Products Inc. $37.3310/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983857 CMS
Mallinckrodt Hospital Products Inc. $57.9910/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983859 CMS
Mallinckrodt Hospital Products Inc. $27.6610/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983861 CMS
Mallinckrodt Hospital Products Inc. $62.5110/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983863 CMS
Mallinckrodt Hospital Products Inc. $43.0510/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983865 CMS
Mallinckrodt Hospital Products Inc. $348.4710/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211983845 CMS
Mallinckrodt Hospital Products Inc. $263.0010/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211983847 CMS
Mallinckrodt Hospital Products Inc. $351.5810/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1211983849 CMS
Mallinckrodt Hospital Products Inc. $149.6610/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983851 CMS
United Therapeutics Corporation $113.8409/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242537434 CMS
Mannkind Corporation $4,387.5007/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1250879855 CMS
United Therapeutics Corporation $94.9905/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242551192 CMS
GlaxoSmithKline, LLC. $20.2204/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191670302 CMS
Insmed, Inc. $116.0903/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186292616 CMS
GlaxoSmithKline, LLC. $24.6801/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190521008 CMS
Mallinckrodt Hospital Products Inc. $20.0201/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211983843 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,137.18 10
PY2020 $14,794.45 9
PY2021 $635.76 11
PY2022 $2,654.19 8
PY2023 $6,309.62 1
PY2024 $2,335.76 12
PY2025 $6,554.98 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $396,736.70 106
PY2024 Principal investigator $84,889.57 23
PY2023 Principal investigator $192,092.54 12
PY2022 Principal investigator $159,264.05 6
PY2021 Principal investigator $302,441.38 5
PY2020 Principal investigator $293,037.53 9
PY2019 Principal investigator $311,581.89 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

106 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 3 Mannkind Corporation $28,429.89 12/10/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898682
Principal investigator 3 Mannkind Corporation $4,200.00 12/10/2025 Non-covered Recipient Entity
UNIVERSITY OF FL
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898684
Principal investigator 4 Mannkind Corporation $10,279.75 12/10/2025 Non-covered Recipient Entity
UNIVERSITY OF FL
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898686
Principal investigator 3 Mannkind Corporation $15,165.00 12/09/2025 Covered Recipient Teaching Hospital
UNIV OF MISSOURI HEALTH CARE
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898386
Principal investigator 3 Mannkind Corporation $3,900.00 12/09/2025 Non-covered Recipient Entity
UNIVERSITY OF FL
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898632
Principal investigator 3 Mannkind Corporation $25,549.87 12/09/2025 Non-covered Recipient Entity
UNIVERSITY OF VIRGINIA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898634
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $675.00 12/08/2025 Non-covered Recipient Entity
University Of Florida
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220802858
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 12/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630345
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 12/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630347
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630397
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630399
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630401
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,166.00 11/12/2025 Non-covered Recipient Entity
University Of Florida
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220802848
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 11/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630341
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 11/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630343
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630391
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630393
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630395
Principal investigator 3 Mannkind Corporation $42,099.44 10/23/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898602
Principal investigator 3 Mannkind Corporation $750.00 10/23/2025 Non-covered Recipient Entity
UNIVERSITY OF IOWA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898604
Principal investigator 4 Mannkind Corporation $3,744.00 10/21/2025 Non-covered Recipient Entity
UNIVERSITY OF FL
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898588
Principal investigator 3 Mannkind Corporation $12,836.63 10/21/2025 Non-covered Recipient Entity
UNIVERSITY OF FL
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898590
Principal investigator 4 Mannkind Corporation $1,350.00 10/21/2025 Non-covered Recipient Entity
UNIVERSITY OF FL
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898592
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39,690.00 10/09/2025 Non-covered Recipient Entity
University Of Florida
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220802856
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 10/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630337
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 10/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630339
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630385
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630387
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630389
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $325.00 09/25/2025 Non-covered Recipient Entity
University Of Florida
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220802846
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 09/24/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630335
Principal investigator 4 Mannkind Corporation $38,464.19 09/16/2025 Non-covered Recipient Entity
UNIVERSITY OF VIRGINIA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898582
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 09/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630331
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 09/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630333
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630367
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630369
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630371
Principal investigator 3 Mannkind Corporation $1,500.00 08/29/2025 Non-covered Recipient Entity
UNIVERSITY OF IOWA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898564
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 08/26/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630373
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630375
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 08/26/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630377
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 08/26/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630379
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 08/26/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630381
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 08/26/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630383
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630327
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630329
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630357
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630359
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630361
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630363
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630365
Principal investigator 1 Boehringer Ingelheim International GmbH $384.85 07/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630321
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 07/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630323
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 07/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630325
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630351
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630353
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630355
Principal investigator 1 Dompe Farmaceutici S.p.A. $109.20 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399006
Principal investigator 1 Dompe Farmaceutici S.p.A. $86.01 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399008
Principal investigator 1 Dompe Farmaceutici S.p.A. $914.71 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399010
Principal investigator 1 Dompe Farmaceutici S.p.A. $300.00 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399012
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,300.00 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399014
Principal investigator 1 Dompe Farmaceutici S.p.A. $3,000.00 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399016
Principal investigator 1 Dompe Farmaceutici S.p.A. $390.00 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399018
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,210.00 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399020
Principal investigator 1 Dompe Farmaceutici S.p.A. $471.63 06/25/2025 Non-covered Recipient Entity
University of Florida
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) No dispute reported 06/30/2026 1248399022
Principal investigator 3 Mannkind Corporation $4,000.00 06/19/2025 Non-covered Recipient Entity
UNIVERSITY OF IOWA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898522
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,033.90 06/09/2025 Non-covered Recipient Entity
University Of Florida
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220802844
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 06/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630313
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 06/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630315
Principal investigator 1 Boehringer Ingelheim International GmbH $384.85 06/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630319
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 06/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220630349
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 05/27/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630317
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $67.96 05/21/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220792607
Principal investigator 3 Mannkind Corporation $11,199.28 05/16/2025 Non-covered Recipient Entity
UNIVERSITY OF VIRGINIA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898502
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $427.50 05/06/2025 Non-covered Recipient Entity
University Of Florida
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220802842
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 05/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630305
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 05/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630307
Principal investigator 1 Boehringer Ingelheim International GmbH $384.85 05/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630311
Principal investigator 1 Insmed, Inc. $1,300.00 04/28/2025 Non-covered Recipient Entity
University of Florida
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651088
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 04/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630297
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 04/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630299
Principal investigator 1 Boehringer Ingelheim International GmbH $384.85 04/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630303
Principal investigator 4 Mannkind Corporation $17,750.92 03/14/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898444
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,814.30 03/10/2025 Non-covered Recipient Entity
University Of Florida
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220802840
Principal investigator 1 Boehringer Ingelheim International GmbH $384.85 03/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630287
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 03/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630289
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 03/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630291
Principal investigator 1 Paratek Pharmaceuticals, Inc. $650.00 02/06/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711070
Principal investigator 1 Paratek Pharmaceuticals, Inc. $325.00 02/06/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711072
Principal investigator 1 Paratek Pharmaceuticals, Inc. $1,040.00 02/06/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711074
Principal investigator 1 Paratek Pharmaceuticals, Inc. $5,915.00 02/06/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex No dispute reported 06/30/2026 1181711076
Principal investigator 1 Boehringer Ingelheim International GmbH $384.85 02/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630281
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 02/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630283
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 02/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630285
Principal investigator 1 Boehringer Ingelheim International GmbH $35.92 02/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630309
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $427.50 01/27/2025 Non-covered Recipient Entity
University Of Florida
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220802838
Principal investigator 1 Insmed, Inc. $1,500.00 01/24/2025 Non-covered Recipient Entity
University of Florida
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651034
Principal investigator 1 Insmed, Inc. $500.00 01/24/2025 Non-covered Recipient Entity
University of Florida
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189651036
Principal investigator 3 Mannkind Corporation $20,653.99 01/21/2025 Non-covered Recipient Entity
UNIVERSITY OF VIRGINIA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898416
Principal investigator 3 Mannkind Corporation $21,965.80 01/06/2025 Non-covered Recipient Entity
UNIVERSITY OF ALABAMA AT BIRMINGHAM
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898392
Principal investigator 4 Mannkind Corporation $24,876.00 01/06/2025 Non-covered Recipient Entity
UNIVERSITY OF IOWA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898394
Principal investigator 3 Mannkind Corporation $29,250.00 01/06/2025 Non-covered Recipient Entity
UNIVERSITY OF VIRGINIA
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898396
Principal investigator 1 Boehringer Ingelheim International GmbH $47.11 01/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630293
Principal investigator 1 Boehringer Ingelheim International GmbH $4.82 01/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630295
Principal investigator 1 Boehringer Ingelheim International GmbH $282.22 01/01/2025 Non-covered Recipient Entity
UF Health Shands Hospital
A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) No dispute reported 06/30/2026 1220630301